Polianta Ltd’s Pfizer PFE Stock Holding History

Polianta Ltd’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-34,571	Closed	-$1.19M	–	87
2017 Q4	$1.19M	Buy	+34,571	New	+$1.18M	0.39%	57

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Polianta Ltd's PFE Position: Q1 2018 in Review

Polianta Ltd sold out of Pfizer (PFE) in Q1 2018, closing a stake of 34,571 shares — an estimated $1.19M sold.

Polianta Ltd first reported a position in PFE in Q4 2017 and held it in 1 quarter. The position peaked at $1.19M in Q4 2017. 2,230 funds tracked by Wall St. Rank hold PFE as of Q1 2018.

Polianta Ltd reported no remaining Pfizer position as of Q1 2018 after selling out during the quarter.
Polianta Ltd sold 34,571 Pfizer shares in Q1 2018, an estimated $1.19M.
Polianta Ltd first reported a position in Pfizer in Q4 2017 and held it in 1 quarter.
Polianta Ltd's Pfizer position peaked at $1.19M in Q4 2017.
2,230 funds tracked by Wall St. Rank held Pfizer as of Q1 2018.

Based on Polianta Ltd's 13F filing for Q1 2018, filed 13 Apr 2018.